Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

IRF4 mutations in chronic lymphocytic leukemia.

Authors: Havelange, V  Pekarsky, Y  Nakamura, T  Palamarchuk, A  Alder, H  Rassenti, L  Kipps, T  Croce, CM 
Citation: Havelange V, etal., Blood. 2011 Sep 8;118(10):2827-9. doi: 10.1182/blood-2011-04-350579. Epub 2011 Jul 25.
Pubmed: (View Article at PubMed) PMID:21791429
DOI: Full-text: DOI:10.1182/blood-2011-04-350579

Interferon regulatory factor 4 (IRF4) is a member of the interferon regulatory factor family of transcription factors and has been shown to have critical functions at several stages of B-cell development. Genome-wide association study identified a polymorphism in the 3' untranslated region of IRF4 as a chronic lymphocytic leukemia risk locus. In this study, we report a recurrent heterozygous somatic mutation in the DNA-binding domain of IRF4 detected in 7 of 457 chronic lymphocytic leukemia patients (1.5%). Patients with IRF4 mutation have a good prognosis, and 4 of 6 have a trisomy 12. We also found that IRF4 mRNA expression is higher in the patients with the mutation.

Annotation

Disease Annotations
Objects Annotated

Additional Information

 
CRRD Object Information
CRRD ID: 11526158
Created: 2016-08-10
Species: All species
Last Modified: 2016-08-10
Status: ACTIVE



NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.